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ABSTRACT Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1) protects cells from 
oxidative stress via the base excision repair pathway and as a redox transcriptional coactiva-
tor. It is required for tumor progression/metastasis, and its up-regulation is associated with 
cancer resistance. Loss of APE1 expression causes cell growth arrest, mitochondrial impair-
ment, apoptosis, and alterations of the intracellular redox state and cytoskeletal structure. A 
detailed knowledge of the molecular mechanisms regulating its different activities is required 
to understand the APE1 function associated with cancer development and for targeting this 
protein in cancer therapy. To dissect these activities, we performed reconstitution experi-
ments by using wild-type and various APE1 mutants. Our results suggest that the redox func-
tion is responsible for cell proliferation through the involvement of Cys-65 in mediating APE1 
localization within mitochondria. C65S behaves as a loss-of-function mutation by affecting the 
in vivo folding of the protein and by causing a reduced accumulation in the intermembrane 
space of mitochondria, where the import protein Mia40 specifically interacts with APE1. 
Treatment of cells with (E)-3-(2-[5,6-dimethoxy-3-methyl-1,4-benzoquinonyl])-2-nonyl prope-
noic acid, a specific inhibitor of APE1 redox function through increased Cys-65 oxidation, 
confirm that Cys-65 controls APE1 subcellular trafficking and provides the basis for a new role 
for this residue.
INTRODUCTION
The apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1) has 
a crucial role in the maintenance of genome stability and redox sig-
naling and has emerged as an excellent target for sensitizing tumor 
cells to chemotherapy (Bapat et al., 2009, 2010; Tell et al., 2010a; 
Tell and Wilson, 2010; Wilson and Simeonov, 2010). In fact, it acts 
as an essential enzyme in the base excision repair (BER) pathway of 
DNA damage caused by both endogenous and exogenous oxidiz-
ing/alkylating agents, including chemotherapeutic drugs. In combi-
nation with thioredoxin (Ueno et al., 1999; Seemann and Hainaut, 
2005), it also acts as a regulatory redox agent to maintain cancer-
related transcription factors (Egr-1, NF-κB, p53, HIF-1α, AP-1, and 
Pax proteins) in an active reduced state (Hirota et al., 1997; Wei et al., 
2000; Ziel et al., 2004; Gray et al., 2005; Pines et al., 2005a, 2005b; 
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Tell et al., 2005, 2010a). APE1 can also function as a transcriptional 
repressor through indirect binding to negative Ca2+-response ele-
ments, which is regulated by K6/K7 acetylation (Bhakat et al., 2003). 
Acetylation occurring on these Lys residues has been recently dem-
onstrated to occur during genotoxic treatment conditions (Yamamori 
et al., 2010) and to inhibit the apoptotic extrinsic pathway triggered 
by Helicobacter pylori infection in gastric epithelial cells while the 
DNA repair function inhibits the intrinsic pathway (Chattopadhyay 
et al., 2010). Recently, APE1 was demonstrated to bind/cleave abasic 
RNA (Vascotto et al., 2009a; Fantini et al., 2010; Tell et al., 2010b) and 
to control c-Myc expression by nicking its mRNA (Barnes et al., 2009). 
These discoveries point to a new function of APE1 in regulating gene 
expression through posttranscriptional mechanisms and open new 
routes to consider this protein as a possible target for anticancer ther-
apy, to be pursued only after elucidation of the molecular details re-
sponsible for its different biological functions.
In this context, we showed that the first 33 amino acids of APE1 
are required for a stable interaction with RNA, nucleophosmin, and 
other proteins involved in ribosome biogenesis/RNA processing 
(Vascotto et al., 2009a). Conversely, the APE1 N-terminal domain 
(spanning the region 35–127) is principally devoted to the redox 
transcriptional activity, whereas the C-terminal domain (region 161–
318) exerts enzymatic activity on DNA abasic sites (Xanthoudakis 
and Curran, 1992; Xanthoudakis et al., 1994). Redox and repair 
functions of APE1 are completely independent; in fact, mutation at 
C65 abolishes the redox function but does not affect the repair one 
(Luo et al., 2008), whereas replacements of a variety of amino acids 
required for DNA repair, such as H309 and others (McNeill and 
Wilson, 2007), do not affect protein redox activity. Although the mo-
lecular mechanism of APE1 repair activity has been delineated 
(Gorman et al., 1997), that of the redox function has not. In fact, 
C65, which is required for this function (Georgiadis et al., 2008), is 
not accessible and resides inside the APE1 structure (Gorman et al., 
1997; Mol et al., 2000; Luo et al., 2008). The absence of a C-X-X-C 
motif, as in the majority of redox regulatory proteins, together with 
an improper position of other APE1 cysteines to act as redox 
exchangers (Luo et al., 2010), hinders the molecular assignment 
of such a regulatory function. Recent in vitro studies showed that 
APE1 adopts different unfolded conformations depending on the 
redox state of its Cys residues (Su et al., 2011); moreover, the APE1 
redox inhibitor (E)-3-(2-[5,6-dimethoxy-3-methyl-1,4-benzoquinonyl)]-
2-nonyl propenoic acid (E3330) was shown to decrease the amount 
of the redox-active protein by driving C65 into disulfide bonds 
(Kelley et al., 2011). Thus it is plausible that APE1 may adopt a par-
tially unfolded state as the redox-active form of the enzyme, as re-
cently suggested (Su et al., 2011). E3330 holds clinical potential as 
a specific inhibitor of APE1 redox function without interfering with 
its endonuclease activity (Fishel and Kelley, 2007). The importance 
of this function is highlighted by results demonstrating that NF-κB–
mediated gene expression is regulated by APE1 redox activity with-
out effects on IκBα degradation (Shimizu et al. 2000; Nishi et al. 
2002). E3330 was also found to selectively inhibit growth/migration 
of human pancreatic cancer cells (Zou and Maitra, 2008), suggesting 
that the APE1 redox function could represent a good candidate for 
inhibition of tumor invasion and metastasis. However, knowledge is 
lacking on the detailed molecular mechanisms responsible for the 
C65-mediated APE1 redox function and on the effects of E3330 in-
hibition on APE1 in vivo.
APE1 subcellular distribution within different mammalian cell 
types is mainly nuclear and critically controls cellular proliferative 
rate (He et al., 2003; Fung and Demple, 2005; Izumi et al., 2005). 
Increased expression of APE1 is associated with different tumori-
genic processes (Tell et al., 2005). In particular, a higher intracellular 
expression and a robust cytoplasmic localization of APE1 have been 
described in lung, ovarian, thyroid, and breast cancers (Tell et al., 
2005), in which they correlate with higher tumor aggressiveness. 
The possible causal role played by this particular distribution in tu-
mor progression is unknown. However, APE1’s ability to activate 
transcription factors, such as p53 and Egr-1 (Huang and Adamson, 
1993; Gaiddon et al., 1999; Seo et al., 2002; Hanson et al., 2005; 
Pines et al., 2005a, 2005b), which are deeply involved in controlling 
cell cycle arrest and apoptotic programs, leaves the debate open 
regarding the mechanisms responsible for modulating its different 
functions in several contexts.
In different cell types, APE1 was proved to localize also in mito-
chondria, where it is involved in BER activity (Tell et al., 2001; 
Chattopadhyay et al., 2006; Szczesny et al., 2008, 2010). Mecha-
nisms regulating APE1 localization and subdistribution are unknown 
(Chattopadhyay et al., 2006; Mitra et al., 2007), even though the 
proteolytic removal of the first 31–33 amino acids at the protein N-
terminus seems to be responsible, at least in part, for promoting 
nuclear exclusion of the protein (Chattopadhyay et al., 2006). Re-
cent work suggested the occurrence of a mitochondrial targeting 
sequence within region 289–318, which is masked by the N-terminal 
domain (Li et al., 2010), thus suggesting the need for specific and 
regulated mechanisms of protein unfolding–refolding to ensure 
proper APE1 localization.
APE1 is essential for cell viability (Xanthoudakis et al., 1996; 
Ludwig et al., 1998; Fung and Demple, 2005), and attempts to 
isolate stable APE1-knockout cell lines have been unsuccessful. 
For these reasons, achieving a comprehensive understanding of 
the molecular mechanisms mediating APE1 different functions has 
been very difficult. In the recent years, however, conditional knock-
out and knockdown strategies (Fung and Demple, 2005; Izumi 
et al., 2005; Vascotto et al., 2009a, 2009b) have made it possible 
to establish cell models to inspect and characterize the major func-
tions of APE1. Nonetheless, knowledge of molecular effectors 
regulated by APE1 in determining its biological roles is still scanty. 
The essentiality of APE1 for mammalian cells seems to be mainly 
due to its DNA-repair activity in the BER pathway. In fact, transcom-
plementation of APE1 deficiency by the yeast homologous Apn1 
(Fung and Demple, 2005), which lacks the redox-transcriptional 
activation domain, were able to recover, although not completely, 
mammalian cells from apoptosis induced by APE1 knockdown. 
However, attempts to restore the repair activity in cells not ex-
pressing APE1 by using an APE1 mutant lacking the acetylation 
sites in Lys-6/7 but not the DNA-repair activity (Izumi et al., 2005) 
were unsuccessful. Moreover, by specifically blocking the APE1 re-
dox activity with the drug E3330 but not its DNA repair activity, it 
was shown that cytokine-mediated hemangioblast development in 
vitro was significantly impaired (Zou et al., 2007). These observa-
tions led us to hypothesize that the essentiality of APE1 may be 
due to its pleiotropic biological effects rather than merely to its 
DNA-repair activity and underline the necessity to elucidate the 
molecular mechanisms responsible for the fine tuning of the differ-
ent APE1 biological functions to fully consider this protein as an 
established target for anticancer therapy.
In this work, we used a reconstitution strategy to reintroduce 
mutant APE1 proteins in APE1-silenced cell clones to determine 
the role of crucial amino acids in protein activities. We generated 
triple stable cell clones expressing ectopic flagged forms of APE1 
wild-type and specific mutant APE1 proteins in an inducible APE1 
small interfering RNA (siRNA) background, checking their ability to 
rescue the biological effects due to endogenous APE1 loss of 
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expression. Our data demonstrate that APE1C65S behaves as a 
loss-of-function mutation affecting the in vivo folding of the pro-
tein and affecting mitochondrial functionality. Experiments with 
E3330 confirmed that C65 is responsible for controlling APE1 sub-
cellular trafficking. Overall, our data shed light on some new mo-
lecular aspects mediating the multifunctional nature of APE1 in 
regulating different biological mechanisms and provide the first in 
vivo evidence of the relevance of C65 in regulating the folding and 
subcellular distribution of APE1.
RESULTS
Reconstitution of APE1 wild type and mutants reveals a role 
for H309, C65, and N-terminal 33 amino acids in mediating 
protein functions responsible for cell viability and growth
Evidence provided by us and others on APE1 multifunctional roles 
in mammalian cells raise several important questions regarding the 
possibilities to 1) discriminate between direct and indirect effects 
due to APE1 loss of expression, 2) investigate how these pleiotropic 
actions are modulated to guarantee a functional specificity, and 3) 
examine what function of APE1 is mainly responsible for its vital role. 
To gain insights into these issues, we used a knock-in strategy ap-
plied to the inducible APE1-silenced clones described previously 
(Vascotto et al., 2009a, 2009b). We generated triple stable cell 
clones expressing ectopic flagged forms of wild-type (WT) and mu-
tant APE1 proteins on an inducible APE1 siRNA background. In par-
allel to WT protein (APE1WT), we expressed the following mutant 
APE1 proteins: 1) the APE1H309N mutant lacking the DNA repair 
function (Masuda et al., 1998; Evans et al., 2000); 2) the APE1C65S 
mutant with no redox activity (Evans et al., 2000); 3) the nonacetylat-
able APE1K6K7/R6R7 mutant (Bhakat et al., 2003); 4) the APE1C310S mu-
tant lacking a recently discovered S-nitrosilation site involved in cy-
toplasmic relocalization of the protein upon nitrosative stress 
(Qu et al., 2007); 5) the double mutant APE1H309N/C310S; and 6) the 
noncleavable APE131-34A mutant, which has been suggested to have 
protective effects on cell viability (Fan et al., 2003). We evaluated 
the rescuing ability of each of these APE1 forms on different bio-
logical parameters previously demonstrated to be affected by APE1 
silencing (Vascotto et al., 2009b), that is, cell growth, apoptosis, mi-
tochondrial functioning, and stress fiber formation. During cell clone 
isolation, although we were able to isolate stably expressing ectopic 
forms of APE1WT, APE1C65S, APE1C310S, APE1K6K7/R6R7, and APE131-34A 
proteins (with a 20–40% of success on 5–20 colonies; see Table 1), 
neither APE1H309N nor APE1C310S/H309N gave positive colonies de-
spite the similar number screened for each mutant (n = 13–20). Our 
further unpublished data (also B. Demple, personal communication) 
clearly showed that this mutation, which abolishes the DNA-repair 
(Masuda et al., 1998) and RNA quality control (Vascotto et al., 2009a; 
unpublished data) activities of APE1 while retaining its ability to 
bind the substrate, results in a protein form toxic to cells. Therefore 
these data do not exclude the possibility that the APE1H309N mutant 
may act as a dominant-negative protein form, being responsible for 
counterselection mechanisms occurring during the colony selection 
process, such that no viable APE1H309N-expressing clones were iso-
lated during cell screening.
Expression of the other mutant APE1 proteins gave variable re-
sults. All positive clones displayed comparable expression levels 
with the ectopic APE1 protein upon endogenous APE1 silencing, as 
determined by Western blot analysis (Figure 1A), and all recombi-
nant ectopic forms localized mainly within the nuclear compartment 
(Supplemental Figure S1). The ectopic expression was always com-
parable to that of the endogenous form before doxycycline treat-
ment, thus showing that our cell model is much more similar to the 
physiological condition than that used in previous studies (Izumi 
et al., 2005). Comparison of cell growth and apoptosis upon endog-
enous APE1 silencing, as measured by clonogeneic assays (Figure 
1B, left) and annexin V staining (Figure 1B, right), respectively, dem-
onstrated a variable ability of the different ectopic proteins to rescue 
the biological effects due to the loss of endogenous APE1. In par-
ticular, whereas the APE1WT protein, as well as the nonacetylatable 
APE1K6K7/R6R7 mutant, resulted in almost complete rescue of cell 
growth, the noncleavable APE131-34A form resulted in a gain-of-func-
tion activity, having even higher viability than APE1WT-expressing 
cells. On the contrary, the APE1C65S mutant was completely unable 
to compensate the loss in cell viability due to endogenous APE1 si-
lencing, thus demonstrating a dominant-negative functional activity. 
The APE1C310S mutant showed an intermediate behavior. Similar to 
cell growth results, the APE1C65S was completely unable to rescue 
from apoptosis induced by APE1 loss of expression. Further analysis 
to determine the mitochondrial function of the different cell clones 
showed that, with the exception of the APE1C65S mutant, all of the 
remainders were able to rescue the drop in mitochondrial mem-
brane potential, Δψm, caused by endogenous loss of APE1 (see 
Table 2). This result suggests that the C65S mutation may play a 
substantial role in affecting the mitochondrial functionality of the 
protein, possibly affecting cell viability. Finally, we found that all 
APE1 mutants successfully prevented loss of stress fiber formation 
due to protein suppression (Table 2).
Knock-in APE1
Number of 
screened 
clones
Number 
of positive 
clones Frequency (%)
Wild type 17 4 23.5
K6K7/R6R7 5 2 40.0
31-34A 15 3 20.0
C65S 5 2 40.0
C310S 6 1 16.6
H309N 20 0 0
H309N+C310S 13 0 0
HeLa cell clones grown in triple-selective medium as described in Materials 
and Methods were replated at low density and incubated for additional 14 d 
for single colonies, which were isolated by using cloning cylinders and then ex-
panded for 10 d in triple-selective medium. The number of positive cell clones 
expressing ectopic APE1 different forms is reported.
TABLE 1: Knock-in colony screening results obtained for wild-type 
and different APE1 mutants.
Knock-in 
APE1
Cell growth 
(colony survival 
assay) Apoptosis Δψm
Stress 
fibers
Wild type +++ ++ +++ +++
K6K7/
R6R7
+++ ++ +++ +++
31-34A ++++ +++ +++ +++
C65S - - + ++
C310S + + +++ +++
The rescue effect of the different APE1 ectopic forms was evaluated as de-
scribed in Vascotto et al. (2009b).
TABLE 2: Rescuing ability of wild-type and different APE1 mutants.
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APE131-34A versus APE1WT, whereas for 
APE1C65S versus APE1WT, 38 probe sets met 
this criterion, in line with the expectations 
suggested by the biological data shown in 
Figure 1. These 38 probe sets included 
genes involved in cell cycle (TGFA, DUSP4, 
and DUSP6) and growth (TGFA, AREG, 
NRG1, and GDF15; Supplemental Table 
S1). Owing to the pleiotropic action of 
APE1, it was impossible to drive any defini-
tive conclusion on the main molecular 
mechanisms at the basis of the observed 
biological phenomena. These results sug-
gest that the APE1C65S mutant exerts its ef-
fects in part through modulating, directly or 
indirectly, the APE1 target gene expression 
profile. However, the limited number of 
genes differentially expressed by the 
APE1C65S mutant with respect to APE1WT 
demonstrates that the biological effects of 
the APE1C65S mutation are not only associ-
ated with its impact on gene expression 
when compared with a previous observa-
tion showing that more than 1100 genes 
were found to be affected by APE1 silenc-
ing (Vascotto et al., 2009b).
Of interest, the APE131-34A mutant did 
not reveal a significantly different gene ex-
pression profile from that shown by APE1WT 
protein. To explore the molecular reasons 
for its gain-of-function phenotype, as shown 
in our cell growth data (Figure 1), additional 
experiments were performed. First, we 
evaluated whether this mutation increased 
APE1 stability. Half-lives of the APE1WT and 
the APE131-34A proteins were evaluated by 
treating reconstituted cells with the protein 
synthesis inhibitor cycloheximide (CHX) and 
by measuring the kinetics of APE1 disap-
pearance through Western blot analysis. 
Figure 2B shows that CHX treatment pro-
moted a time-dependent disappearance of 
the full-length APE1 band with a similar ki-
netics for both proteins, with an approxi-
mate half-life of 8 h. In the case of APE1WT, 
the disappearance of the full-length form 
was paralleled by a progressive increase of 
a truncated form (NΔ 33APE1) missing the 
first 33 amino acids at the protein N-termi-
nus (Chattopadhyay et al., 2006), which was 
not visible in the case of the APE131-34A mu-
tant. Thus the 31-34A mutation does not seem to directly affect 
protein half-life. We therefore evaluated the role of APE131-34A mu-
tant in protecting cells from the apoptosis-inducing agents rotenone 
and etoposide. Similar to CHX treatment, we found that exposure of 
cells to these compounds induced the accumulation of the trun-
cated form of APE1 in the case of APE1WT-expressing cells but not 
in the case of APE131-34A-expressing cells (Figure 2C). Indeed, 
the caspase-3/7 activation assay (Figure 2D) showed that the 
APE131-34A-expressing cells were significantly more resistant to 
apoptosis (induced by both rotenone and etoposide) than the 
APE1WT-expressing ones. On the basis of these data, we conclude 
FIGuRE 1: Rescuing abilities of wild-type and different APE1 mutants. (A) Schematic 
representation of the human APE1 protein with indication of functional domains and mutants 
used for KI studies. (B) Inducible APE1 siRNA HeLa cell clones were stably transfected with the 
p3XFLAG-CMV-14 empty or encoding for APE1WT or APE1K6K7/R6R7, APE131-34A, APE1C65S, or 
APE1C310S mutant. After selection, different clones were assayed for the expression of the 
endogenous and the ectopic APE1 forms before and after expression of the specific APE1 
siRNA sequence through doxycycline treatment. Scr-1 indicates the control-siRNA transfected 
cell line. Assays were performed by immunoblotting with the specific anti-APE1 antibody or 
anti-tubulin as loading control. (C) Left, rescuing abilities on cell growth of different ectopic 
APE1 forms after silencing of endogenous APE1 through inducible-expressed siRNA, as 
measured by colony survival assays. Five hundred cells of control and siRNA clones were seeded 
in Petri dishes and then treated with 1 μg/ml doxycycline for 10 d. Data are the mean ± SD of 
three independent experiments. Right, evaluation of apoptosis by annexin V staining on ectopic 
APE1-expressing cell lines. Details are as on the left. Data are the mean ± SD of three 
independent experiments.
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C65S and 31-34A mutations affect APE1 functions through 
different mechanisms
To gain more insight into the molecular effects caused by the knock-
in experiments (Figure 1 and Table 2), we performed gene expres-
sion profiling through microarray analysis. We concentrated on two 
mutations because of their opposite effects: C65S, a loss-of-func-
tion mutation, and 31-34A, a gain-of-function mutation. The plot in 
Figure 2A shows that the APE1C65S mutant affected the global gene 
expression profile, in comparison with that of the wild type, more 
than the APE131-34A mutant. In fact, after statistical analysis of dif-
ferential expression, no probe sets had a q value of <0.05 for 
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that the proteolytic removal of the N-termi-
nal part of APE1 is associated with the onset 
of an apoptotic phenotype but does not af-
fect the overall protein half-life in vivo. This 
effect was not simply due to the loss of the 
NLS sequence leading to the inhibition of 
nuclear localization, since the APE1NΔ33 mu-
tant retained the ability to reside within the 
nuclear compartment even if a significant 
cytoplasmic localization was evident 
(Vascotto et al., 2009a). Recent data from 
our laboratory demonstrated that the non-
conserved protein N-terminus is essential to 
modulate APE1–protein interactions, APE1’s 
role in the RNA-cleansing process (Vascotto 
et al., 2009a; Tell et al., 2010b), and APE1’s 
DNA-repair function through modulation of 
its catalytic activity (Fantini et al., 2010). 
Thus this unstructured portion of the pro-
tein seems to act as an important molecular 
switch for regulating the different APE1 
functions (Tell et al., 2010a).
C65 is critical for chaperone-mediated, 
redox-dependent folding of APE1 
in vivo
To better inspect the reasons for the loss-of-
function behavior of the APE1C65S mutant, 
we analyzed the effect of this mutation on 
the protein endonuclease activity over aba-
sic double-stranded DNA (dsDNA) by cleav-
age assay (Fantini et al., 2010). It was re-
cently shown that the C65S mutation does 
not significantly affect the enzymatic activity 
of APE1 with respect to the WT protein 
when using recombinant purified proteins 
FIGuRE 2: C65S and 31-34A mutations affect APE1 function by different mechanisms. C65S 
mutation, but not 31-34A, affects APE1 influence on gene expression. (A) Differential gene 
expression profiling in APE1C65S and APE131-34A vs. APE1WT-expressing clones. Log2 ratio scatter 
plots comparing expression profiles from the APE1 rescue experiments (mean expression from 
biological replicas made in triplicate). For APE131-34A vs. APE1WT, only 113 probe sets with a fold 
change greater than 2 were observed; for APE1C65S vs. APE1WT, 985 probe sets with a similar 
fold change were found. Only for the APE1C65S vs. APE1WT were statistically significant probe 
sets (38) found (Supplemental Table 1). (B) 31-34A mutation does not affect APE1 protein 
half-life. HeLa cells were transfected with APE1WT and APE131-34A constructs, as reported in 
Materials and Methods. The day after transfection, protein expression was inhibited by 
treatment with cycloheximide (100 μg/ml) up to 24 h to evaluate APE1 half-life. Thirty 
micrograms of total cellular extracts was separated by 12% SDS–PAGE and then transferred 
onto a nitrocellulose membrane. The membrane was immunoblotted with anti-FLAG or 
anti-actin antibodies. Left, CHX treatment causes a progressive disappearance of the 37-kDa 
protein band corresponding to the full-length APE1 protein and a concomitant accumulation of 
the truncated 34-kDa protein form (arrow) lacking the N-terminal part. This is evident only 
when expressing the APE1WT form but not the APE131-34A mutant. Right, normalized volume 
values of band intensities obtained after densitometric analysis of the ratio between the 37-kDa 
APE1 form and β-actin reported as histograms. Black and dashed boxes indicate APE1WT and 
APE131-34A expression levels, respectively. Data shown are the mean of two independent 
experimental sets. (C) Treatment with apoptosis-inducing agents causes proteolysis of APE1WT 
but not APE131-34A protein. HeLa cells were transfected with APE1WT- and APE131-34A-expressing 
plasmid, as reported in Materials and Methods, and then treated with etoposide and rotenone 
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for the indicated times. Expression of 
ectopic APE1WT and APE131-34A proteins was 
assayed by immunoblotting. Forty 
micrograms of total cellular extracts was 
separated by 12% SDS–PAGE and then 
transferred onto a nitrocellulose membrane. 
The membrane was immunoblotted with 
anti-FLAG or anti–β-actin antibodies. 
Treatments induced the accumulation of the 
truncated APE1NΔ33 form of the protein only 
in the case of the APE1WT protein but not 
when expressing the APE131-34A mutant. 
(D) The APE131-34A mutant plays a protective 
role toward drug-induced apoptosis. After 
silencing of endogenous APE1 protein, 
APE1WT and APE131-34A clones were treated 
with etoposide and rotenone for 24 h and 
then caspase-3/7 activation was measured, 
as described in Materials and Methods. 
The histograms show the average ± SD of 
the fluorescence values obtained in three 
independent experiments. Cells expressing 
the APE131-34A mutant protein were 
significantly more resistant to apoptosis than 
the APE1WT-expressing cells. The p value was 
calculated by Student’s t test.
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FIGuRE 3: APE1 endonuclease activity on abasic dsDNA is reduced by the expression of the 
redox mutant C65S. (A) After silencing of endogenous APE1 protein, 2-μg nuclear extracts 
from APE1WT and APE1C65S mutant clones were separated on 12% SDS–PAGE and then 
blotted onto a nitrocellulose membrane, which was subsequently incubated with anti-FLAG or 
anti-TBP (TATA binding protein) antibodies as loading control. (B) Reported amounts of 
normalized nuclear extract from APE1WT and APE1C65S clones were used to evaluate APE1’s 
endonuclease activity on abasic dsDNA. The conversion of the radiolabeled tetrahydrofuran-
containing oligonucleotide substrate (S) to the shorter incised product (P) was evaluated on a 
denaturing 20% (wt/vol) polyacrylamide gel. In each reaction, 2.5 pmol of double-stranded 
tetrahydrofuran containing DNA oligonucleotide (dsFDNA) was used. A representative image 
from three independent experiments is shown. (C) Average values of incision percentage with 
standard deviations of three independent experiments.
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expressed in bacteria (Mantha et al., 2008). However, this finding 
cannot exclude the possibility that this mutation may affect the 
APE1 endonuclease activity in vivo. This is reinforced by the obser-
vation made by different laboratories that the endonuclease activity 
of purified bacterially expressed recombinant APE1 is significantly 
reduced (at least 100-fold lower) with respect to that obtained from 
mammalian cells (HeLa; data not shown). Thus we compared the 
APE1 enzymatic activity in nuclear extracts from APE1WT- and 
APE1C65S-expressing cells. Results shown in Figure 3C clearly dem-
onstrate that the enzymatic activity of APE1C65S mutant is signifi-
cantly lower than that of the APE1WT pro-
tein, accounting for a role in the biological 
effects seen in Figure 1.
Because Cys residues can drive the fold-
ing process of a protein in vivo through se-
quential protein–protein interaction steps 
(Herrmann and Riemer, 2010b), we hypoth-
esized that C65S mutation could affect the 
interactomic network of APE1. By using a 
proteomic approach described previously 
(Vascotto et al., 2009a), we analyzed the 
changes in the APE1 interactome as a con-
sequence of C65S mutation. The interacto-
mic map of APE1C65S clearly showed an in-
creased presence of two protein species 
with respect to that of APE1WT (Figure 4, A 
and B). These were identified as peroxire-
doxin-6 (PRDX6) and protein disulfide-
isomerase A3 (PDIA3 or ERp57). Of interest, 
both are known to be involved in redox-as-
sisted protein-folding processes in mamma-
lian cells. Thus their increased interaction 
with the APE1C65S mutant may account for 
impairment in the kinetics of the redox-fold-
ing process for this mutant with respect to 
APE1WT.
The possible effect of C65 residue on the 
structural folding of APE1 in vivo was evalu-
ated by limited proteolysis studies on immu-
nopurified APE1WT and APE1C65S proteins. 
Time-course analyses by using trypsin and 
chymotrypsin as proteolytic enzymes are 
shown in Figure 4, C and D, respectively. Al-
though the final pattern of proteolytic frag-
ments generated upon digestion was similar 
for APE1WT and APE1C65S mutants, the kinet-
ics of proteolysis showed a quite different 
behavior, thus suggesting a differential re-
sponse of the proteins to proteolytic attack 
and confirming the role of C65 in controlling 
the proper folding of APE1 in vivo.
C65 is critical for mitochondrial 
localization of APE1 in cells, and 
C65S mutation causes mitochondrial 
impairment
Redox folding and interaction with PRDX6 
and PDIA3 may constitute a mechanism af-
fecting APE1 localization into the mitochon-
drial compartment. Moreover, based on the 
observations that APE1C65S-reconstituted 
cells showed a significant impairment of mi-
tochondrial functionality (Table 2), we characterized the role of C65 
residue by analyzing the effect of the C65S mutation on the amount 
of mitochondrial protein levels recoverable in the HeLa cells used in 
this work. Initially, we verified that the knock-in strategy (i.e., expres-
sion of an ectopic APE1 recombinant protein) did not affect the 
expression of the endogenous protein within mitochondria (unpub-
lished data). As demonstrated in Figure 5A, the total amount of 
ectopic APE1 after 10 d of doxycycline treatment was comparable 
in APE1C65S and APE1WT clones. Of interest, the amount of APE1C65S 
protein in mitochondria was significantly lower (∼60%) than the WT 
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stimuli we used H2O2 and rotenone. To 
measure the mitochondrial function alter-
ations occurring after oxidative stress, we 
performed two different assays for evalu-
ating changes in both Δψm and mitochon-
drial membrane permeability. As shown in 
the dot plots of JC-1 staining (Figure 5C), 
those cells with Δψm loss appeared to be 
associated with a decreased FL2 signal 
or/and an increased FL1 signal (right/
lower shift). When treated with H2O2 and 
rotenone for 3 h, Δψm in all cell lines sig-
nificantly dropped, and the amplitude of 
the Δψm decrease was dose dependent. 
In APE1-deficient cell lines, including 
knockdown (siRNA) and redox-mutant 
forms (APE1C65S), however, more cells un-
derwent Δψm loss when compared with 
their counterparts (Scr-1 and APE1WT) sep-
arately (Figure 5D). Continuous Δψm loss 
usually causes mitochondrial impairment 
and membrane leakage, which conse-
quently leads to the release of proapop-
totic factors, such as cytochrome c, from 
mitochondria to cytoplasm, thus deter-
mining initiation of the apoptotic cascade. 
The results shown in Figure 5E indicate 
that cytochrome c was increased in cyto-
solic fraction after H2O2 or rotenone treat-
ment; this occurred even more signifi-
cantly in APE1-knockdown and APE1C65S 
mutant cell lines. These data are consis-
tent with the observed Δψm alterations 
and clearly demonstrate that mitochon-
drial function of APE1-deficient and 
APE1C65S-reconstituted cells is impaired in 
response to oxidative stress and may in-
duce apoptosis through a mitochondrial-
dependent pathway.
APE1 interacts with the redox 
chaperone Mia40
By using purified mitochondria from bo-
vine heart as a reliable source for organelle 
subfractionation, we then investigated 
APE1 localization in the mitochondrial 
compartment. We treated mitochondria 
with digitonin to selectively disrupt the 
outer membrane and to separate the inter-
membrane space (IMS) and the matrix, two 
mitochondrial compartments enriched in 
soluble proteins. Figure 6A shows that 
APE1 in purified mitochondria is a full-
length protein of ∼37 kDa and is mainly 
located within the IMS. The APE1 localiza-
tion pattern was different from that of the 
complex II of the oxidative phosphoryla-
tion chain, used as a marker of the inner membrane in the different 
mitochondrial subfractions, and of polymerase γ, which was de-
scribed as a non–free soluble matrix protein of the mitochondrial 
BER system (Stuart et al., 2005). Both were confirmed to be in the 
inner membrane/matrix fraction.
protein (Figure 5B). These data demonstrated that this mutation af-
fects proper accumulation of APE1 in mitochondria.
We then examined whether the biological effects of C65S 
mutation (Figure 1 and Table 2) are due to impairment of the 
mitochondrial function following oxidative stress; as oxidant 
FIGuRE 4: APE1C65S redox mutant interacts more strongly with PDIA3 and PRDX6 than APE1WT. 
(A) Differential two-dimensional electrophoresis analysis of the APE1-FLAG protein complex 
immunopurified under native conditions from APE1WT and APE1C65S mutants demonstrated the 
occurrence of a stronger interaction of the C65S mutant with PDIA3 and PRDX6 proteins. 
Results were obtained by silver staining and mass spectrometry identification of the proteins 
coimmunopurified with APE1-FLAG. (B) Western blotting analysis of a coimmunoprecipitated 
material from an independent experiment. Total cell extracts from HeLa cells (Mock) and APE1WT 
and APE1C65S clones were coimmunoprecipitated, normalized for immunoprecipitated APE1 
protein, and then analyzed by 10% SDS–PAGE. Immunoblotting using specific antibodies 
(α-APE1, α-PDIA3, α-PRDX6) confirmed the differential interaction of APE1WT and APE1C65S 
clones with PDIA3 and PRDX6. Total cell extract was used as a positive control. Absence of 
signal in the mock line confirmed the specificity of these interactions. (C) Limited proteolysis 
analysis of the immunopurified APE1WT and APE1C65S proteins after trypsin (left) and 
chymotrypsin (right) treatment. After incubation with proteolytic enzymes for the reported 
times, proteins were separated on 12% SDS–PAGE and then blotted onto a nitrocellulose 
membrane, which was further immunoblotted with anti-APE1 antibody. Although the final 
pattern of proteolytic fragments generated upon digestion (highlighted by arrows) was similar 
for APE1WT and the APE1C65S mutant, their kinetics of proteolysis showed a significantly different 
behavior. These difference indicates a dissimilar folding state of the two proteins. A 
representative image from three independent experiments is shown.
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E3330 treatment impairs APE1 subcellular trafficking, 
confirming that redox folding controls APE1 cellular 
distribution
To elucidate the role of C65 in regulating the APE1 folding and 
thus its subcellular trafficking, we used the redox inhibitor E3330, 
which has been reported to directly interact with this protein and 
to inhibit its redox activity by increasing the formation of disulfide 
bonds by Cys-65 (Shimizu et al., 2000; Nishi et al., 2002) and de-
creasing the protein redox active population (Su et al., 2011). In 
this context, we used a tumor cell model represented by the hu-
man glioblastoma cell line SF767 (Hirose et al., 2003). Treatment of 
cells for 6 h with increasing doses of E3330 caused a significant 
Due to its significant molecular mass, mitochondrial localization 
of APE1 should require active processes of transportation. The 
main chaperone responsible for redox-assisted folding processes 
within the IMS of mitochondria in mammals is Mia40 (Riemer et al., 
2011). Therefore we determined whether Mia40 might interact 
with APE1 through proximity ligation assay (PLA) analysis, which 
allows in situ detection of two proteins that are at interacting dis-
tance range (<40 nm; Weibrecht et al., 2010). As shown in Figure 
6B, we were able to demonstrate a specific signal of APE1 interac-
tion with Mia40 within the cytoplasm of HeLa cells, accounting for 
the occurrence of a physical interaction between the two proteins, 
which may explain the localization of APE1 within the IMS.
FIGuRE 5: APE1C65S mutation affects APE1 mitochondrial accumulation and causes mitochondrial impairment. 
(A) Western blotting analysis of total cell extracts from HeLa cells and APE1WT and APE1C65S clones confirmed that APE1WT 
and APE1C65S ectopic proteins were expressed at similar levels within the cells. (B) Western blotting analysis of 
mitochondrial extract from HeLa cells and APE1WT and APE1C65S clones by using anti-FLAG and anti–complex II (α-CII) 
antibodies showed that C65S mutation impairs APE1 translocation within mitochondria. Right, relative histogram plotting 
the average percentage values of ectopic recombinant flagged APE1WT and APE1C65S proteins normalized for α-CII and 
for total APE1 content into HeLa cells ± SD of three independent experiments. (C) JC-1 assay of mitochondrial membrane 
potential loss in APE1 knockdown (siRNA) and APE1C65S mutant clones after oxidative stress; Scr-1 and APE1WT clones 
were used as controls separately. To induce oxidative stress, different doses of H2O2 and rotenone were dissolved in the 
medium and incubated with cells for 3 h, then stained with JC-1 probe and immediately measured by using flow 
cytometry; only 200 μM H2O2 and 5 μM rotenone doses are displayed in the graph. (D) Histograms for JC-1 assays. The 
percentage of cell population undergoing MMP loss was scored in cells treated with different doses of both H2O2 and 
rotenone for 3 h. Data show the average values ± SD from three independent experiments. (E) The release of cytochrome 
c (α-CytC) after oxidative stress in APE1-knockdown (siRNA) and APE1C65S-mutant clones was assayed after 6 h of 200 μM 
H2O2 or 5 μM rotenone treatment. Scr-1 and APE1WT clones were also evaluated for comparison. Cytosolic fractionation 
was performed excluding the mitochondrial fraction by differential centrifugation. The content of cytochrome c in 
cytosolic fraction, representing the permeability of mitochondrial outer membrane and activation of mitochondrial 
pathways of apoptosis, was measured by Western blotting. β-Actin was also detected as a control for loading equality.
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distribution. Immunofluorescence experi-
ments (Figure 7, B and C, left) clearly dem-
onstrated that a significant relocalization of 
APE1 from the nuclear to the cytoplasmic 
compartment occurred with no significant 
alterations in total protein levels, as mea-
sured by Western blot analysis (Figure 7C, 
right). Moreover, kinetic experiments also 
showed that E3330 treatment caused a 
progressive emptying of the nucleoli, as 
confirmed by anti-nucleophosmin staining 
analysis (Figure 7C, bottom, and Supple-
mental Figure S2). Altogether, these data 
demonstrate that the redox state of C65 
controls the subcellular trafficking of APE1 
and that E3330 effects are associated with 
alterations of APE1 trafficking.
DISCUSSION
Comprehension of the molecular signaling 
networks underlying the multifaceted action 
of APE1 is at its beginning. In particular, a 
pair of questions remain open in explaining 
why attempts to completely revert apopto-
sis due to APE1 suppression via sole target-
ing of the DNA-repair enzymatic activity of 
this protein were unsuccessful: 1) How are 
protein pleiotropic actions modulated to 
guarantee functional specificity? 2) What is 
the function of APE1 that is mainly respon-
sible for its vital role?
To address these issues, we used an un-
biased strategy to investigate the ability of 
different APE1 mutants, targeting specific 
known functions, to recover from the bio-
logical changes associated with APE1 loss 
of expression. Of interest, rescue experi-
ments provided strong evidence for a de-
termined and hierarchical role of specific 
APE1 amino acids in controlling the differ-
ent biological protein functions. Our inabil-
ity to isolate any cell clone expressing the 
APE1H309N mutant strongly indicated that 
complete abolition of DNA-repair and/or 
RNA quality control activities of this protein, 
although retaining its ability to binding sub-
strate, is toxic for cells, as previously sug-
gested (Fung and Demple, 2005). On the 
basis of gene expression profiling, the 
APE131-34A-mutant rescue was indistinguish-
able from that exerted by APE1WT, as also 
expected on the basis of the biological re-
sults obtained in this study; no genes with 
statistically significant differential expres-
sion were observed. Thus we inspected in more detail the mecha-
nisms possibly explaining the gain-of-function effect of this mutant. 
On the basis of data reported in Figure 2, B–D, we can conclude 
that the proteolytic removal of the N-terminal part of APE1 leads to 
its functional inactivation in vivo without affecting protein half-life. 
We believe that the nonconserved protein N-terminus, which is re-
sponsible for modulating protein–protein interactions, is devoted 
to regulation of different APE1 functions in an indirect way, as 
FIGuRE 6: Mitochondrial APE1 is accumulated within the IMS of mitochondria and interacts in 
vivo with the mitochondrial IMS import and assembly protein 40 (Mia40). (A) Mitochondria from 
bovine hearth were fractionated with digitonin and subsequent differential centrifugation to 
separate matrix and IMS, which are compartments rich in soluble proteins. Sixty micrograms of 
total mitochondrial extract (M), matrix plus inner membrane fraction (IM), and intermembrane 
space (IMS) fraction alone was separated onto 12% SDS–PAGE and then blotted onto a 
nitrocellulose membrane, which was further immunoblotted with anti-APE1, anti–Poly γ, and 
anti–complex II (α-CII) antibodies. Western blotting analysis showed that only the full-length 
protein was present within the mitochondrial fractions, and APE1 was predominantly found in 
the IMS fraction rich of soluble proteins. Polymerase γ, used as marker of non–freely soluble 
matrix protein of the mitochondrial BER system, was confirmed to be associated with the inner 
membrane–containing particulate fraction. Total mitochondria extracts were used as a positive 
control; complex II was used as a marker of the inner membrane. Average percentage values of 
APE1 normalized for CII ± SD of three independent experiments are plotted in the relative 
histogram (right) of Western blot analysis (left). (B) PLA technology was used to demonstrate the 
occurrence of the interaction between APE1 and Mia40. PLA reaction was performed following 
manufacturer’s instructions. Confocal microscopy analysis highlighted the presence of distinct 
fluorescent red dots (PLA signals) indicating the occurrence of in vivo interaction between APE1 
and Mia40; green fluorescence shows the APE1 localization within the cell. Negative control is 
represented by cells incubated only with α-APE1 antibody.
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reduction of mitochondrial functioning, as measured by 3-(4,5- 
dimethylthiazol-2-yl )-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) cell viability assay (Figure 7A), 
without causing any apparent apoptotic process at early times of 
treatment (unpublished data). The maximal extent of this effect 
was obtained at 140 μM E3330 treatment. To confirm the effect of 
E3330 on APE1 subcellular trafficking, we used this dose of drug 
and performed kinetics experiments to evaluate APE1 subcellular 
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FIGuRE 7: APE1 redox inhibitor E3330 affects APE1 nuclear localization on human glioblastoma 
cell line SF767. (A) MTS cell viability assay on SF767 after 6 h of treatment with increased 
amounts of E3330 showed a progressive reduction of viable cells in proliferation as a 
consequence of the treatment. E3330 was resuspended in 100% dimethyl sulfoxide (DMSO); 
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control is represented by cells treated with 
the same volume of DMSO used for the 
highest dose of E3330. (B) APE1 subcellular 
localization was detected through confocal 
analysis using a specific APE1 monoclonal 
antibody derivatized with Alexa Fluor 568. 
4′,6-Diamidino-2-phenylindole was used for 
nuclear staining and differential interference 
contrast to observe cellular shape. In control 
cells, APE1 mainly localized within the nuclear 
compartment and accumulated into nucleoli. 
Treatment with 140 μM E3330 induced an 
early (1–4 h) and progressive reduction of 
APE1 nucleolar positivity, followed by a 
complete nuclear emptying and cytoplasm 
accumulation of APE1. (C) APE1 nuclear 
intensities of control and E3330-treated cells 
were measured with Metamorph analysis 
software, indicating a statistically significant 
(p < 0.001) reduction of APE1 nuclear 
positivity after 6 h of 140 μM E3330 
treatment (upper left). On the contrary, this 
treatment did not affect APE1 protein 
expression, as demonstrated by Western 
blotting analysis on total cell extracts (upper 
right). As loading control, nitrocellulose 
membrane was incubated with anti-tubulin 
antibody. Histograms below represent the 
statistical analyses of APE1 subcellular 
distribution performed in up to 300 cells 
(nuclear positivity, nucleolar and nuclear 
emptying) for each time point of E3330 
treatment (bottom, center).
suggested by our recent work (Vascotto 
et al., 2009a; Fantini et al., 2010; Tell et al., 
2010a, 2010b). An additional intriguing hy-
pothesis, which is under evaluation, is that 
the truncated APE1 may play an active role 
in apoptotic triggering. Further work is 
needed to clearly address this point.
The APE1K6K7/R6R7 mutant, in our cell 
model, was able to rescue from apoptosis 
induced by endogenous APE1 deprivation 
obtained through a specific siRNA silencing 
strategy in stable cell lines (Figure 1C). 
These data seem partially in contrast with 
those previously published (Izumi et al., 
2005). However, it is remarkable to note the 
significantly different biological system used 
by these authors with respect to ours, in 
terms of: 1) cell type used (mouse normal 
fibroblasts vs. human tumor HeLa cells) and 
2) generation of the model (Cre-knockout 
gene vs. siRNA knockdown in HeLa cells) 
and the procedure chosen for reconstitution 
with ectopic APE1 forms (microinjection vs. 
stable cell cloning). Thus, in our approach, 
alternative mechanisms able to compensate 
for some subtle APE1 functional deficien-
cies could have been selected during the 
cloning procedures. Thus these selection 
procedures could have hidden some differ-
ences particularly under basal conditions 
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from different laboratories. Actually, the role of C65 in controlling 
APE1 redox function, as supported by published evidence (Walker 
et al., 1993; Su et al., 2011), contradicts the single work of Ordway 
et al. (2003), which reported the lack of any major phenotype altera-
tion in APE1C64A (homologous to human APE1C65A) transgenic mice. 
We believe that our findings on APE1C65S mutant, on tumor cells, are 
not in contrast with previous work but rather reinforce current knowl-
edge on the central role of C65 in redox-assisted folding of APE1 in 
vivo. Its impact on protein subcellular distribution should be inter-
preted on the basis of the cell context in which experimental obser-
vations were obtained and of the presence of compensatory mecha-
nisms present in transgenic mice (Ordway et al., 2003). Our present 
data support a role for C65 in controlling subcellular trafficking of 
APE1 that may affect, in turn, the biological functions of the protein, 
including DNA-repair in cells. Owing to the differential essentiality of 
this activity for mammalian cells, an impairment of the redox-medi-
ated folding process of APE1 may have different effects, depending 
on the cell type and cellular conditions. In addition, due to the rele-
vance of APE1 protein for different cell lines, different biological 
mechanisms could be switched on to compensate for reduced/im-
paired APE1 function. It would be expected, in fact, that the biologi-
cal impact of C65A mutation could be more relevant under patho-
logical conditions associated with increased oxidative stress or 
tumorigenic process. Unpublished data confirm these hypotheses. 
Notably, the quite heterogeneous expression levels of APE1 protein 
in different cell lines, and thus its importance, should be taken into 
account. Whereas fibroblasts express ∼105 APE1 molecules/cell 
(Cappelli et al., 2001), tumor cells like the HeLa we used here express 
∼107 molecules per cell (unpublished data). In the work by Ordway 
et al. (2003) all biochemical assays were performed with mouse em-
bryo fibroblast cells under normal conditions, and thus it is possible 
that the discrepancies with our data could be ascribed to these pro-
foundly different experimental conditions from a biological point of 
view. An alternative explanation about the difference from the results 
of Ordway et al. (2003) could in principle be ascribed to the choice 
of the mutation. In fact, the substitution of the Cys with a Ser could 
be different from Ala because Cys-65 is a buried residue in the three-
dimensional structure and, as expected, the Cys-to-Ala mutation has 
no effect on the local folding of the molecule (Georgiadis et al., 
2008). In this environment, Ser could be destabilizing for local struc-
ture due to its hydrophilic nature. In any case, since it has been re-
cently demonstrated that Cys-65 (together with Cys-93) is the more 
oxidizable residue of APE1 (Su et al., 2011), thus supporting a model 
in which a conformational transition implying solvent exposure is 
required for exerting the redox activity of Cys-65, the Cys-to-Ser mu-
tation better resembles this condition occurring during the redox 
function of APE1 and causing partial protein unfolding. Thus, Cys to 
Ser is a better mimic of an “open” conformation of this domain of 
APE1, whereas Cys to Ala better mimics a “closed” conformation. In 
this light, both mutations will give partial but not contrasting informa-
tion about the real biological condition of the APE1 redox state.
We have also demonstrated here that APE1 accumulates within 
the IMS of mitochondria and that C65 integrity is essential for pro-
tein subcellular localization. Notably, despite the hundreds of pro-
teins present within the matrix of mitochondria, only 50–100 have 
been described to occur within the IMS (Riemer et al., 2011). Of in-
terest, those mitochondrial proteins present within the matrix are 
initially synthesized on cytosolic ribosomes as precursor proteins 
carrying N-terminal MTSs, which direct them into mitochondria, 
where they are proteolytically removed in the matrix by matrix pro-
cessing peptidases (Chacinska et al., 2009). In contrast, mitochon-
drial proteins present within IMS mostly lack these classical MTS 
of cell growth, in which the majority of our experiments were per-
formed while underscoring the most important functional deficien-
cies of the H309N and C65S mutants. In this regard, it is expected 
that using some genotoxic stimuli might highlight the functional rel-
evance of further mutants, and work is in progress in our lab along 
these lines. Recent work showed increased caspase-3 activation oc-
curring in APE1K6K7/R6R7 mutant with respect to the APE1WT protein. 
These results, which were obtained in gastric epithelial cells only 
upon H. pylori infection and not under basal conditions (Chattopad-
hyay et al. 2010), would confirm our hypothesis. On the other hand, 
our cell model has the advantage of having a strict and controlled 
amount of ectopic APE1 protein level, which is comparable in the 
different cell lines and, most important, is similar to the endogenous 
one, which has been replaced. Izumi et al. (2005) could not check for 
this important parameter in light of the relevance of a proper APE1 
expression level in mammalian cells, and Chattopadhyay et al. (2010) 
used an overexpression cell model triggered with an oxidative 
stress–inducing stimulus (by H. pylori infection), two conditions quite 
different from ours. APE1 expression levels are homeostatically reg-
ulated in mammalian cells through control of protein turnover (Busso 
et al., 2009) and at the gene expression level through a negative 
feedback loop involving APE1 itself (Kuninger et al., 2002). Of inter-
est, the absolute amount of APE1 protein is significantly variable, 
depending on cell type and growth condition (see later discussion). 
For these reasons, cell models based on overexpression strategies 
like those described by Chattopadhyay et al. (2010) and Izumi et al. 
(2005) might better resemble a condition of cell activation in terms 
of APE1 expression. Our reconstitution cell model, on the other 
hand, may well represent a more physiological condition in which 
cells are selected to survive by only expressing the ectopic recombi-
nant protein under nonstressing conditions.
Mutation of C65 residue, which is responsible for controlling the 
redox activity of APE1, displayed a loss-of function-effect toward cell 
growth and viability. Of interest, the mild alteration of the gene 
expression profiling of APE1C65S-expressing cells with respect to 
APE1WT ones points to a role for the redox activity of APE1 in control-
ling expression of genes involved in cell cycle and cell growth. In any 
case, this alteration may not represent per se the major cause of the 
loss-of-function effect we observed, at least under basal cellular con-
ditions. Rather, our data clearly highlight the central role of C65 in 
redox-assisted folding of APE1 in vivo, which affects mitochondrial 
localization of the protein. In fact, C65S mutation alters the folding 
process of APE1 and controls its interaction with PDIA3 (Figure 4), a 
protein containing thioredoxin-like domains and having chaperone 
activity (Grillo et al. 2006). Thus it could be hypothesized that 1) 
APE1C65S may induce a misshapen conformation associated with an 
increased affinity toward PDIA3 (Figure 4), and this could reduce the 
fraction of APE1 available to translocate into mitochondria; and 2) 
C65 may promote a redox-dependent conformational change to-
ward a more translocatable protein form, thus behaving as an essen-
tial redox sensor. In this context, the absence of C65 would make 
APE1C65S unable to efficiently respond to oxidative stress and trans-
locate into mitochondria. The reduced mitochondrial amount ob-
served for the APE1C65S mutant should explain the biological effects 
associated with expression of this protein, which leads to a reduced 
cell viability as a consequence of mitochondrial impairment. The re-
sults reported in this study are then in agreement with recent evi-
dence, obtained in vitro with purified recombinant proteins, showing 
a role for C65 in mediating the redox-assisted folding of APE1 (Kelley 
et al., 2011; Su et al., 2011). Our data extend these observations to 
the in vivo relevance for this unexpected mechanism and provide the 
molecular basis to explain apparently contradictory observations 
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recruited as a function of the cellular status is required to fully 
address this complex issue, thus translating this unique protein 
from bench top to bedside.
In summary, our data represent the first attempt, to our knowl-
edge, at gaining a global view of the molecular role of APE1 within 
the cell. By combining large-scale studies with classic biochemical 
approaches, we demonstrated that the wild-type APE1 protein has 
structural components functioning in several distinct cellular roles, 
providing a molecular basis for explaining its multifunctional bio-
logical activity. The data set coming from this work also offers sev-
eral scientific leads for future studies aimed at shedding light on the 
subtle mechanisms of this control.
MATERIALS AND METHODS
Cell lines and materials
Both HeLa and SF767 (provided by the Brain Tumor Research Cen-
ter, University of California at San Francisco, San Francisco, CA) cell 
lines were grown in DMEM (Invitrogen, Carlsbad, CA) supplemented 
with 10% fetal bovine serum (Euroclone, Milan, Italy), 100 U/ml pen-
icillin, and 10 μg/ml streptomycin sulfate. All chemical reagents 
were supplied by Sigma (Milan, Italy) unless otherwise specified.
Inducible siRNA of APE1 and generation of APE1 
knock-in cell lines
For inducible silencing of endogenous APE1 and reconstitution with 
different APE1 proteins, HeLa cell clones were developed as de-
scribed (Vascotto et al., 2009a, 2009b) and as reported in the Supple-
mentary Information. For inducible siRNA experiments, doxycycline 
(Sigma) was added to the cell culture medium at the final concentra-
tion of 1 μg/ml, and cells were grown for 10 d. All biological data 
were reproduced in at least two different cell clones for each model.
Preparation of cell extracts and anti-FLAG 
coimmunoprecipitation
Preparation of total cell lysates and coimmunoprecipitation analyses 
were performed as described (Vascotto et al., 2009a, 2009b) and as 
reported in the Supplemental Information.
Cell growth assays and apoptosis studies
All cell growth assays and apoptosis studies were performed as de-
scribed (Vascotto et al., 2009a, 2009b) and detailed in the Supple-
mental Information.
Endonuclease assays
The determination of AP endonuclease activity of APE1 was per-
formed as reported (Vascotto et al., 2009a) and detailed in the 
Supplemental Information.
Limited proteolysis studies
Approximately 4 μg of APE1WT and APE1C65S immunopurified pro-
teins from reconstituted HeLa cells were subjected to limited prote-
olysis for the reported time by using trypsin (6 fmol) and chy-
motrypsin (24 fmol) in 0.1 M ammonium bicarbonate buffer (10 μl 
final volume). Proteolysis was blocked by adding 4 μl of Laemmli 
sample buffer 4× and incubating samples at 95°C for 5 min. Then 
samples were loaded onto 12% SDS–PAGE and transferred to nitro-
cellulose membranes for further Western blotting analysis with spe-
cific anti-APE1 antibody (Vascotto et al., 2009a).
Immunofluorescence analysis and proximity ligation assay
Immunofluorescence analyses on HeLa or SF767 cells were per-
formed as described (Vascotto et al., 2009a) and detailed in the 
sequences and use alternative routes for mitochondrial import, 
generally relying on the Mia40-Erv1 disulfide relay system 
(Herrmann and Riemer, 2010a, 2010b). APE1 completely lacks a clas-
sic N-terminal MTS sequence (Tell et al., 2001; Chattopadhyay et al., 
2006), and the molecular mechanisms regulating its mitochondrial 
trafficking are unknown. Recently, Li et al. (2010) suggested that resi-
dues spanning the region 289–318 are important for APE1 mito-
chondrial localization upon menadione-induced oxidative stress, 
being essential for interaction within the outer membrane Tom20cd 
translocase. They pointed that oxidative stress promotes APE1 mito-
chondrial accumulation, which is enhanced when testing 
K24/25/27/31>A APE1 mutants. They also discussed that their 
model could not explain the impact of an altered cellular redox state 
on modulating the amount of mtAPE1. The result reported in this 
study demonstrate that Mia40 specifically interacts with APE1, which 
provides further support to the hypothesis of the involvement of a 
redox-mediating folding process of APE1 affecting its subcellular dis-
tribution. Thus our data further extend the model proposed by Li 
et al. (2010) toward a plausible explanation causally linking the cel-
lular redox state and APE1 mitochondrial trafficking. Further work is 
needed to characterize in detail the specific mechanisms regulating 
APE1 mitochondrial translocation and involving Mia40. However, this 
is the first time to our knowledge that such a model has been pro-
posed. Notably, we recently demonstrated that some of the afore-
mentioned K residues important for APE1 mitochondrial accumula-
tion undergo acetylation in vivo (Fantini et al., 2010). It is plausible 
that both acetylation of critical K residues and C65 redox status may 
regulate the conditional translocation of APE1 within mitochondria, 
controlling protein accumulation there. This model would provide a 
molecular basis, based on quick and reversible posttranslational 
modifications (PTMs), for the rapid mechanism required for regulat-
ing APE1 subcellular trafficking on cellular vital sites, such as in mito-
chondria, where oxidative stress mainly exerts its damaging effects.
Our inability to fully rescue cells from APE1 silencing-induced 
apoptosis with the APE1C65S mutant strongly supports the redox ac-
tivity of APE1 as an ideal candidate target for pharmacological inter-
vention and cancer therapeutics. Data obtained with the E3330 in-
hibitor (Figure 7) strongly confirm the reliability of this approach and 
provide molecular evidence for a direct effect of this compound in 
vivo. Recent data clearly demonstrate that bifunctional therapy, in-
cluding DNA-damaging agents (such as treatment with alkylating 
agents or ionizing radiation or radiomimetics treatment) and inhibi-
tion of DNA-repair enzymes activities, may represent a promising 
direction in cancer treatment (Helleday et al., 2008; Tell and Wilson, 
2010). Therefore knowledge of the molecular mechanisms regulat-
ing key enzymes in DNA repair has a fundamental importance for 
developing new anticancer strategies.
In addition to basic research aimed at the understanding the 
molecular mechanisms responsible for the fine tuning of the dif-
ferent APE1 functions, development of small-molecule inhibi-
tors of each function will be necessary to ultimately define which 
protein activity is preponderant in normal and cancer cells. Re-
cent findings on redox inhibition of APE1 have potential clinical 
significance (Kelley and Fishel, 2008; Kelley et al., 2011; Reed 
et al., 2009; Fishel et al., 2010); they suggested that a redox in-
hibitor could be used as a single agent, in combination with 
current treatments, or as a potential antigrowth, cytostatic 
agent. Obviously, for proper modulation of different intercon-
nected functions of multifunctional proteins like APE1, fine-
tuned regulation of these activities is required. Better under-
standing of the processes controlling APE1 subcellular 
distribution, of its PTMs, and of its different interacting partners 
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Transient transfection studies
HeLa cells (0.3 × 106 cells/60-mm dish) were transfected using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
protocol with 200 ng of the pcDNA5.1-APE1-c-FLAG plasmid, en-
coding for the C-terminal FLAG-tagged WT APE1 or the 31-34A 
mutant; the pcDNA5.1-empty vector was used as control.
Preparation of crude mitochondria from cells and of 
mitochondrial subfractions from bovine heart
Mitochondria isolation was performed as previously reported 
(Abou-Khalil et al., 1985). Subconfluent HeLa cells were collected 
and suspended at a concentration of 2 × 107 cells/ml in mitochon-
drial isolation buffer (250 mM sucrose, 1 mg/ml BSA, 2 mM EDTA, 
pH 7.4) with 1:100 protease inhibitor cocktail (Sigma). Cell suspen-
sions were sonicated on ice under mild controlled conditions to dis-
rupt selectively plasma membranes (5-s sonication repeated three 
times, with 30-s intervals). The homogenates (∼95% of disrupted 
cells) were then fractionated by differential centrifugation at 800 × g 
and 16,000 × g at 4°C, to obtain the enriched mitochondria pellet. 
Purity of mitochondria was judged on the basis of low cross-contam-
ination (6–16%) of marker proteins H3acK18, Hsp70, and calreticulin 
during semiquantitative analysis of Western blots for the nucleus, 
cytoplasm, and endoplasmic reticulum, respectively.
Bovine heart mitochondria (BHM) were isolated as previously de-
scribed (Ferguson et al. 1977). Subfractions were prepared by incu-
bation of BHM on ice with digitonin (0.18 mg/mg protein), followed 
by centrifugation at 35,000 × g for 15 min at 4°C to separate mito-
plasts (matrix plus inner membrane) from intermembrane space 
soluble, protein-rich fractions (Bisetto et al., 2008). Membrane in-
tegrity of mitoplasts was judged on the basis of the malate dehydro-
genase (matrix enzyme) activity, which was 83% of that in BHM 
(Gallet et al., 1999).
JC-1 assay for mitochondrial membrane potential
The mitochondrial membrane potential, Δψm, was assessed by using 
the JC-1 Mitochondria Staining Kit (Sigma-Aldrich, St. Louis, MO) for 
flow cytometry, following the manufacturer’s recommendations. 
Cells were treated with various doses of different drugs for the indi-
cated times, then incubated in medium containing JC-1 probe at 
desired working concentration for 30 min at 37°C. After double 
washing with JC-1 binding buffer, Δψm was measured immediately 
by using flow cytometry. JC-1 is a mitochondrial-selective sensor 
and aggregates in normal and highly polarized mitochondria, result-
ing in a red emission of 590 nm after excitation at 490 nm. On depo-
larization of the mitochondrial membrane, JC-1 forms green fluores-
cent monomers and determines an increase in the green/red (FL1/
FL2) fluorescence intensity ratio. Thus the loss of JC-1 aggregates 
directly correlates with changes of Δψm. Valinomycin, a mitochon-
drial membrane potential disrupter, was used as a positive control.
Cytochrome c release assay
To measure the cytochrome c release from mitochondria to cyto-
plasm following oxidative stress, mitochondria-free cytosolic 
fractions were subjected to Western blot analysis by using an 
antibody against cytochrome c. Mitochondria-free cytosolic frac-
tion was prepared by using a protocol described before (Li et al., 
2008). Briefly, 5 × 107 cells were washed once with 10 ml of grind-
ing buffer and collected by centrifugation at 800 × g for 5 min at 
4°C. The pellet was resuspended in 200 μl of grinding buffer and 
sonicated on ice at 30 W for 15 s. Approximately 50–70% of cell 
lysis was ensured under microscope. The supernatant was 
immediately centrifuged at 8500 × g for 20 min at 4°C to pellet 
Supplemental Information. To study the interaction of APE1 with 
Mia40 in vivo, we used in situ PLA technology (Olink Bioscience, 
Uppsala, Sweden). After incubation with APE1 antibody (as previ-
ously described), cells were incubated with anti-Mia40 polyclonal 
antibody (Abcam, Cambridge, MA) diluted 1:50 in blocking solution, 
at 4°C, overnight. PLA was performed following manufacturer’s in-
struction. Briefly, species-specific secondary antibodies, conjugated 
with oligonucleotides (PLA probes), were used, followed by hybrid-
ization with two oligonucleotides and ligation joining of the two hy-
bridized oligonucleotides to a closed circle. During the amplification 
step, the oligonucleotide arm of one of the PLA probes acted as a 
primer for a rolling-circle amplification (RCA) reaction using the li-
gated circle as a template and generated a concatameric (repeated 
sequence) product extending from the oligonucleotide arm of PLA 
probe. In the detection step, fluorescently (Cy3) labeled oligonucle-
otides hybridized to the RCA product. The signal was easily visible as 
a distinct fluorescent red dot, which was detected through confocal 
microscopy. Technical controls, represented by the omission of 
Mia40 primary antibody, resulted in the complete lost of PLA signal.
Cells were visualized through a Leica TCS SP laser-scanning con-
focal microscope (Leica Microsystems, Wetzlar, Germany) and a 63× 
oil fluorescence objective (Figure 6B and Supplemental Figure S1) 
or an Olympus FluoView FV1000 MPE confocal/multiphoton system 
(Olympus, Center Valley, PA) and a Plan Apo N 60×/1.42 oil objec-
tive (Olympus; Figure 7B and Supplemental Figure S2). Determina-
tion of APE1 fluorescence and statistical analysis were performed 
with Metamorph analysis software, version 7.7.1 (Molecular Devices, 
Downingtown, PA).
Western blot analysis and antibodies
Reported amounts of nuclear and cytoplasmic extracts obtained 
from HeLa and SF767 cells were electrophoresed onto a 12% 
SDS–PAGE. Proteins were then transferred to nitrocellulose mem-
branes (Schleicher & Schuell, Keene, NH). Membranes were satu-
rated by incubation with 5% nonfat dry milk in PBS/0.1% Tween 20 
for 1 h at 25°C and then incubated with the specific primary anti-
body [anti-APE1 monoclonal, 3 h at 25°C, dilution 1:2000; anti-
FLAG (Sigma) monoclonal, 3 h at 25°C, dilution 1:1000; anti-PRDX6 
(Abcam) polyclonal, overnight at 4°C, dilution 1:1000; anti-PDIA3 
polyclonal (Abcam), overnight at 4°C, dilution 1:1000; anti-CytC 
monoclonal (Santa Cruz Biotechnology, Santa Cruz, CA), overnight 
at 4°C, dilution 1:500; anti–Pol γ polyclonal (Abcam) overnight at 
4°C, dilution 1:500; anti-CII monoclonal (Invitrogen) overnight at 
4°C, dilution 1:2000]. After three washes with PBS/0.1% Tween 20, 
membranes were incubated for 2 h at 25°C with a secondary 
antibody coupled to peroxidase (Sigma). Then membranes were 
washed three times with phosphate-buffered saline/0.1% Tween-20, 
and the blots were developed using the enhanced chemilumines-
cence procedure (GE Healthcare, Piscataway, NJ). Normalization 
was performed with the polyclonal anti-actin or anti–β-tubulin anti-
bodies (Sigma). Blots were quantified by using a Gel Doc 2000 vid-
eodensitometer (Bio-Rad, Hercules, CA).
Interactomic analysis
Identification of differential protein-interacting partners of APE1C65S 
was performed as described (Vascotto et al., 2009a, 2009b); details 
are reported in the Supplemental Information.
Microarray analysis
Gene expression studies were performed as described previ-
ously (Vascotto et al., 2009b) and detailed in the Supplemental 
Information.
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the mitochondria. The obtained supernatant contained the cyto-
solic fraction.
Statistical analysis
Statistical analysis was performed by using the Excel (Microsoft, 
Redmond, WA) data analysis program for Student’s t test analysis. 
p < 0.05 was considered statistically significant.
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